SYRE

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sheet with $463 million gross proceeds from an underwritten public offering of common stock $1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026, with expected runway into the second half of 2029 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases (“RD”), today announced its first quarter 2026 financial results and provided program and corporate updates. “With our first Phase 2 readout of the year supporting a potential best-in-class profile for SPY001 in IBD, we have begun to deliver on the promise of what we believe is one of the most ambitious and differentiated pipelines in our industry. This result opened the possibility that our monotherapies could become valuable products in IBD and further strengthened our conviction that our combination therapies have the potential to deliver paradigm-changing efficacy for the more than two million Americans suffering from IBD,” said Cameron Turtle, DPhil, Chief Executive Officer of Spyre. “We have now begun enrolling our IBD combination therapies across the world and look forward to unveiling additional monotherapy results over the next few months and combination data next year. Outside IBD, we are advancing a potentially first- and best-in-class anti-TL1A antibody across multiple rheumatic diseases, where we continue to execute ahead of schedule and see significant opportunity for this mechanism paired with a convenient dosing profile. Collectively, we believe our assets, strategy, and execution position Spyre to deliver meaningful outcomes for patients and substantial long-term value for shareholders.” Development Pipeline Overv...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Tuesday reported a loss of $69 million in its first quarter. On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 74 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 66 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SYRE at https://www.zacks.com/ap/SYRE

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre’s website at https://ir.spyre.com/events-and-presentations. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com. For Investors: Eric McIntyre, Spyre Therapeutics SVP of Finance and Investor Relations [email protected] For Media: Josie Butler, 1AB [email protected]

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study Strengthened the balance sheet with an underwritten public offering of common stock in October 2025 and announced the appointment of Kate Tansey Chevlen as Chief Commercial Officer (CCO) $757 million of cash, cash equivalents, and marketable securities as of December 31, 2025, with expected runway into the second half of 2028 WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced its fourth quarter and full year 2025 financial results and provided program and corporate updates. “This year is a pivotal period for Spyre as we begin to unveil results from our two groundbreaking Phase 2 trials with the potential to identify multiple products that leapfrog today's standard of care and provide substantially improved therapies for patients suffering from severe autoimmune diseases. In IBD, we plan to reveal initial safety and efficacy data for our optimized antibodies against the most compelling targets in the space. If successful, these results would support our view that our antibodies are the ideal components for combination therapies with the potential to transform the treatment paradigm in this disease,” said Cameron Turtle, DPhil, Chief Executive Officer of Spyre. “Beyond IBD, we are moving full speed ahead with a potentially first- and best-in-class anti-TL1A antibody in a basket study of three rheumatic diseases. Numerous sources of evidence support potential efficacy of TL1A inhibition in these indications, and our quarterly or twice-annual subcutaneous dosing profile could be the leading product profile in these large markets. Taken together, we believe our assets, strategy, and execution can deliver meaningfu...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $62.5 million in its fourth quarter. On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 70 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 66 cents per share. For the year, the company reported a loss of $155.2 million, or $1.98 per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SYRE at https://www.zacks.com/ap/SYRE

Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The treatment is being tested for curing inflammatory bowel disease and rheumatic diseases. During the trial, SPY003 showed a half-life of approximately 85 days, supporting maintenance dosing of three or six months. Management noted that the trial was randomized, double-blind, and placebo-controlled with 59 healthy volunteers at various doses. In addition, the drug also demonstrated a favourable safety profile, with no serious adverse events. On the same day, Julian Harrison of BTIG maintained Spyre Therapeutics, Inc. (NASDAQ:SYRE) with a Buy rating and a $70 price target. He noted that the extended half-life supports less frequent dosing, which is a critical advancement for SPY003 as a valuable component in combination therapies. Moreover, Harrison also mentioned the company’s unique ability to combine multiple monoclonal antibodies into a single treatment. In terms of finances, the analyst noted the company to be well-positioned with a substantial cash runway to fund operations till the second half of 2028. Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a clinical-stage biotechnology company that develops antibody-based therapies for inflammatory bowel disease and other immune-related conditions. While we acknowledge the potential of SYRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Spyre Therapeutics recently announced positive interim Phase 1 results for its investigational antibody SPY003, showing good tolerability and a long half-life, with plans to advance into Phase 2 studies and ongoing capital-raising efforts supporting continued development. An interesting insight is the company's improved financial performance over the last quarter and nine months, reporting a net loss reduction and a lower basic loss per share compared to the previous year. We will explore how the encouraging Phase 1 SPY003 results shape Spyre Therapeutics' investment narrative and potential for future clinical progress. Find companies with promising cash flow potential yet trading below their fair value. For those considering Spyre Therapeutics, the big picture centers on belief in its pipeline’s ability to deliver new treatments across inflammatory diseases, with near-term value closely linked to the pace and outcome of clinical milestones. This week’s positive interim Phase 1 data for SPY003 adds meaningful momentum, reducing immediate risk around tolerability and pharmacokinetics, and improving the outlook for the SKYLINE Phase 2 study, the next significant catalyst on the horizon. At the same time, Spyre is still a pre-revenue biotech with ongoing losses and a history of shareholder dilution; recent fundraising helps solidify funding, but the share price has recently experienced high volatility, and there’s been significant insider selling. The crucial shifts are that short-term risk tied to the SPY003 program appears somewhat reduced following the data readout, but meaningfully positive or negative updates in upcoming Phase 2 results will still be key drivers of value. On the flip side, frequent board changes and insider selling remain significant points investors should be aware of. Our comprehensive valuation report raises the possibility that Spyre Therapeutics is priced higher than what may be justified by its financials. Two Simply Wall St Community members submitted fair value estimates for Spyre Therapeutics, ranging widely from US$5.27 up to US$52.73 per share. While optimism around recent trial progress may motivate some, others remain cautious about the company’s financial losses and history of dilution. Explore these differing viewpoints to see how your outlook compares. Explore 2 other fair value estimates on Spyre Therapeutics - why the sto...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Tuesday reported a loss of $11.2 million in its third quarter. On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 15 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 68 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SYRE at https://www.zacks.com/ap/SYRE

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA") On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened balance sheet with $316 million gross proceeds from an underwritten public offering of common stock $783 million of pro forma cash, cash equivalents, and marketable securities as of September 30, 2025, with expected runway into the second half of 2028 WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced its third quarter 2025 financial results and provided program and corporate updates. “We have now reported positive Phase 1 data for each of our four investigational antibodies, fully unlocking the breadth of our innovative Phase 2 trials evaluating product candidates with potential indication-leading profiles in diseases that together impact more than five million Americans," said Cameron Turtle, DPhil, Chief Executive Officer of Spyre. “With optimized monotherapies and uniquely differentiated combination therapies in IBD, and a potential first- and best-in-class anti-TL1A therapy in rheumatic diseases, our portfolio could redefine the standard of care in indications totaling over $60B in annual revenue. We anticipate 2026 will be a transformational year for the company as we expect to unveil six Phase 2 proof-of-concept readouts in these indications. With our world-class development organization, de-risked biology, and a recently-strengthened balance sheet, we are poised to deliver meaningful value for patients and shareholders alike.” Development Pipeline Overview and Update The Company is pioneering long-acting antibodies and antibody combinations to redefine the standard of care in IBD and rheumatic diseases. IBD is a chronic condition characterized by inflammation within the...

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination therapies for IBD with potential for indication-leading efficacy, safety, and dosing profiles SPY003 expected to advance to the ongoing Part A of the SKYLINE Ph2 platform trial SKYLINE and SKYWAY trials are expected to provide 6 proof-of-concept readouts in 2026 WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced positive interim Phase 1 results from its first-in-human trial of SPY003, an investigational, extended half-life antibody targeting the p19 subunit of IL-23. "These encouraging Phase 1 data for SPY003 mark our fourth successful first-in-human trial in the past year, underscoring the strength of our antibody engineering platform and efficiency of our development organization,” said Deanna Nguyen, M.D., SVP of Clinical Development at Spyre. “Advancing SPY003 into SKYLINE represents a pivotal step in realizing our vision for a comprehensive IBD portfolio that includes three optimized monotherapies and three uniquely differentiated combinations that have the potential to be dosed on a quarterly or twice annual basis.” Key Phase 1 Interim Findings The SPY003 Phase 1 trial was a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and pharmacokinetic (PK) in healthy volunteers. The trial enrolled 59 healthy adult participants into five single-ascending dose (SAD) cohorts, a multiple dose cohort (MD), and a Chinese ethnobridging (Ch Eb) single dose cohort. Doses of SPY003 evaluated included 200 mg IV, 600 mg SC (two formulations), 600 mg IV, and 1200 mg IV (as single and multiple doses). Interim findings from the trial as of September 19th, 2025 data cutoff include: Safety: SPY003 was well tolerated at all dose levels, with a favorable safety profile consistent with the anti-IL-23 class. There were two Grade 2 or above treatment-emergent adverse events (TEAEs), both deemed not treatment-related, and no serious advers...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Tuesday reported a loss of $36.7 million in its second quarter. The Waltham, Massachusetts-based company said it had a loss of 49 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 73 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SYRE at https://www.zacks.com/ap/SYRE